Disease-Modifying Treatments for Progressive Supranuclear Palsy

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Progressive Supranuclear Palsy (PSP) research focuses on disease-modifying treatments, primarily targeting tau pathology.
• Previous clinical trials of agents like tideglusib and davunetide targeting tau dysfunction or microtubule stabilization have unfortunately failed to demonstrate efficacy.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Progressive Supranuclear Palsy (PSP).
• To highlight the critical need for validated biomarkers in the development of effective PSP treatments.

Main Methods:

• Review of recent clinical trial outcomes for PSP therapeutics.
• Discussion of novel therapeutic approaches including tau-targeting agents, immunotherapies, and gene silencing techniques.
• Exploration of the role of biomarkers, particularly PET imaging with tau-specific ligands, in future clinical trial design.

Main Results:

• Several disease-modifying treatments for PSP targeting tau dysfunction have shown limited success in recent placebo-controlled studies.
• A variety of novel therapeutic strategies are under investigation, including extracellular tau reduction and modulation of tau expression.
• The absence of validated biomarkers remains a significant hurdle for interpreting trial results and advancing therapeutic development.

Conclusions:

• Despite setbacks, research into novel PSP therapies targeting tau pathology and microtubule stabilization continues.
• Validated biomarkers, potentially including tau-specific PET imaging, are essential for future clinical trials to assess treatment efficacy accurately.
• There is optimism that the next decade may yield the first effective therapy for Progressive Supranuclear Palsy.